Immunotech Biopharm reports pre-IPO share option scheme cancellation

Immunotech Biopharm Ltd. reported no change in its authorized share capital, which remains at 5,000,000,000 ordinary shares with a par value of $0.001 per share, totaling $5,000,000. The number of issued shares also held steady at 514,584,000 during the month, with no new shares issued or treasury shares transferred.

A significant movement occurred in the company's Pre-IPO Share Option Scheme, where 26,780,000 options were cancelled. This resulted in 9,150,000 options outstanding at month-end, and led to an increase of 9,150,000 issued shares. The total number of shares that may be issued upon exercise of all options under the Pre-IPO scheme is now 0. The Post-IPO Share Option Scheme reported no options outstanding or new issuances during the month.

The company's Convertible Bonds remained at 300,000,000 yuan, with a subscription/conversion price of HK$4.81, potentially allowing for the issuance of 68,493,150 shares. Overall, the total authorized share capital at the end of September 2025 remains $5,000,000.